6827 studies found for:    "breast cancer"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer
Conditions: Cancer of the Breast;   Breast Cancer;   Advanced Breast Cancer;   Metastatic Breast Cancer;   Male Breast Cancer;   Triple Negative Breast Cancer;   ER+ Breast Cancer
Interventions: Drug: Female AR(+) TNBC Enzalutamide Naïve;   Drug: Female AR(+) TNBC Enzalutamide Treated;   Drug: Female ER(+) BC Patients;   Drug: Male ER(+) BC Patients
2 Active, not recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
3 Completed Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: Carboplatin;   Drug: background treatment
4 Active, not recruiting Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: nab-Paclitaxel;   Drug: Paclitaxel
5 Terminated GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Triple Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI;   Drug: GDC -0941
6 Active, not recruiting Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer;   Stage IV Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: Abraxane;   Drug: Tigatuzumab
7 Active, not recruiting Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Biological: sargramostim;   Drug: rintatolimod;   Other: laboratory biomarker analysis
8 Not yet recruiting A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older
Conditions: Breast Cancer;   Estrogen Receptor Positive Breast Cancer;   Node-negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: Other: Breast Cancer Treatment Decision Aid for women 70+;   Other: Usual Care
9 Recruiting Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors
Conditions: Breast Neoplasms;   Breast Cancer;   Breast Carcinoma;   Malignant Neoplasm of Breast;   Cancer of Breast;   Mammary Neoplasm, Human;   Human Mammary Carcinoma;   Malignant Tumor of Breast;   Mammary Cancer;   Mammary Carcinoma;   Anxiety;   Fear;   Neoplasm Remission, Spontaneous;   Spontaneous Neoplasm Regression;   Regression, Spontaneous Neoplasm;   Remission, Spontaneous Neoplasm;   Spontaneous Neoplasm Remission
Interventions: Behavioral: Acceptance and Commitment Therapy;   Behavioral: Survivorship Education;   Behavioral: Usual Care
10 Terminated Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
Conditions: Breast Cancer;   HER2 Positive Breast Cancer;   Metastatic Breast Cancer;   Cancer of the Breast
Interventions: Drug: IPI-504;   Drug: Trastuzumab
11 Terminated Capecitabine in Women With Operable Breast Cancer
Conditions: Invasive Breast Carcinoma;   Primary Invasive Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Intervention: Drug: Capecitabine
12 Active, not recruiting Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Conditions: HER2-Negative Breast Cancer;   Triple Negative Breast Cancer;   Breast Cancer;   Cancer of Breast;   Breast Tumors
Interventions: Drug: E7389 (Eribulin Mesylate);   Drug: Vinorelbine injection
13 Recruiting Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Ductal Breast Carcinoma With Predominant Intraductal Component;   Lobular Breast Carcinoma in Situ;   Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Tubular Ductal Breast Carcinoma
Interventions: Radiation: accelerated partial breast irradiation;   Radiation: intensity-modulated radiation therapy;   Radiation: image-guided radiation therapy;   Procedure: therapeutic conventional surgery;   Other: questionnaire administration;   Other: laboratory biomarker analysis
14 Recruiting Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
Conditions: Breast Cancer;   Node-positive Breast Cancer;   Breast Adenocarcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma In Situ
Interventions: Radiation: External Beam Radiation Therapy;   Other: Questionnaire Administration;   Other: Laboratory Biomarker Analysis
15 Active, not recruiting A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
Conditions: Taxane-induced Peripheral Neuropathy;   Chemotherapy-induced Peripheral Neuropathy (CIPN);   Early-Stage Breast Carcinoma;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Procedure: Immediate Acupuncture Group;   Procedure: Delayed Acupuncture Group
16 Recruiting Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Conditions: Breast Cancer;   Metastatic Breast Cancer;   Recurrent Breast Cancer
Interventions: Drug: Pemetrexed;   Drug: Sorafenib
17 Completed A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer
Conditions: Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer;   Breast Cancer;   Locally Advanced
Intervention: Drug: gemcitabine, epirubicin, paclitaxel
18 Active, not recruiting Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Skin Metastases;   Stage IV Breast Cancer
Interventions: Drug: imiquimod;   Drug: Abraxane;   Other: laboratory biomarker analysis;   Genetic: RNA analysis;   Other: immunoenzyme technique
19 Active, not recruiting Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: AZD2281;   Drug: Paclitaxel
20 Withdrawn Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
Conditions: Breast Cancer;   Metastatic Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Ixabepilone;   Drug: Capecitabine;   Drug: Motesanib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years